Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phthalimide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 4/20 | 0.56 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.56 |
| ▸ | ACVR1 known ✓ | Q04771 | 1/20 | 0.56 |
| ▸ | MAOA known ✓ | P21397 | 5/20 | 0.50 |
| ▸ | MAOB known ✓ | P27338 | 4/20 | 0.50 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 0.46 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.46 |
| ▸ | PRKCG known ✓ | P05129 | 1/20 | 0.46 |
| ▸ | PRKCB known ✓ | P05771 | 1/20 | 0.46 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.46 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.46 |
| ▸ | PRKCA known ✓ | P17252 | 1/20 | 0.46 |
| ▸ | PRKCH known ✓ | P24723 | 1/20 | 0.46 |
| ▸ | PRKCI known ✓ | P41743 | 1/20 | 0.46 |
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 0.46 |
| ▸ | PRKCQ known ✓ | Q04759 | 1/20 | 0.46 |
| ▸ | PRKCZ known ✓ | Q05513 | 1/20 | 0.46 |
| ▸ | PRKCD known ✓ | Q05655 | 1/20 | 0.46 |
| ▸ | PRKD1 known ✓ | Q15139 | 1/20 | 0.46 |
| ▸ | S1PR4 known ✓ | O95977 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalimide SCHEMBL31266621 | 1.00 | GSK3B (0.94) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL27389200 | 1.00 | GSK3B (0.94) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL30479210 | 1.00 | GSK3B (0.94) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL9421750 | 1.00 | GSK3B (0.94) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL9421751 | 1.00 | GSK3B (0.94) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL29555966 | 1.00 | GSK3B (0.94) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL6890306 | 0.97 | GSK3B (0.88) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL11040503 | 0.97 | GSK3B (1.00) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL29366030 | 0.97 | GSK3B (1.00) | GSK3BCASP7CASP3CASP6CASP8 | |
| Phthalimide SCHEMBL64 | 0.97 | GSK3B (1.00) | GSK3BCASP7CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415355-A | Benzdioxan derivative and its medicinal usage | 奥赖恩公司 | 2019-03-01 | — | — | CN | claimed |
| EP-1758583-A2 | ARYLPIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-03-07 | — | — | EP | claimed |
| WO-2005118537-A2 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2005-12-15 | — | — | WO | claimed |
| US-12610949-B2 | Heteroaryl-triazole compounds as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-28 | — | — | US | disclosed |
| EP-4041393-B1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | BAYER AG (DE) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025228547-A1 | PROCESSES FOR PREPARING PHENETHYLAMINE COMPOUNDS | CYBIN IRL LIMITED (IE) | 2025-11-06 | — | — | WO | disclosed |
| WO-2025073251-A1 | COMPOUND CAPABLE OF DEGRADING EPIDERMAL GROWTH FACTOR RECEPTOR, AND USE THEREOF | 普美瑞(苏州)生物科技有限公司 | 2025-04-10 | — | — | WO | disclosed |
| WO-2025011623-A1 | CYANOQUINOLINE-TARGETING PROTEIN DEGRADATION MOLECULE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海壹迪生物技术有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-119136783-A | Buffer-containing compositions and methods of use thereof | 诺欧生物有限责任公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118027003-A | PROTAC compound, preparation method thereof and application of PROTAC compound as estrogen receptor degradation agent | 山东大学 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-03-28 | — | — | US | disclosed |
| US-6420390-B1 | ANALGESIC AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-07-16 | — | — | US | disclosed |
| CN-1328553-A | 3-Tetrahydropyridin-4-yl indoles for treatment of psychotic disorders | DUPHAR INT RES (NL) | 2001-12-26 | — | — | CN | disclosed |
| US-5889004-A | PSYCHOLOGICAL DISORDERS, ANALGESICS | HOECHST MARION ROUSSEL, INC. (US) | 1999-03-30 | — | — | US | disclosed |
| CN-1037510-C | Indole derivatives | HOFFMANN LA ROCHE (CH) | 1998-02-25 | — | — | CN | disclosed |
| CN-1136275-A | Arylheterocyclylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics | HOECHST ROUSSEL PHARMA (US) | 1996-11-20 | — | — | CN | disclosed |
| CN-1088576-A | Indole derivatives | HOFFMANN LA ROCHE (CH) | 1994-06-29 | — | — | CN | disclosed |
| EP-0428928-A2 | Substituted aminals | BAYER AG (DE) | 1991-05-29 | — | — | EP | disclosed |
| CN-1040366-A | Butenoic acid or acrylic acid derivative | EISAI CO LTD (JP) | 1990-03-14 | — | — | CN | disclosed |
| US-4431807-A | PARASITICIDES; MALARIA; TISSUE AND BLOOD DISORDERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1984-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12610949-B2 | Heteroaryl-triazole compounds as pesticides | CTRL, PTMS, DDT | PARP1 3541/4885PDGFRA 3314/4885ACVR1 3062/4885 |
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | PARP1 8/4885PDGFRA 975/4885ACVR1 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.